Seuk K. Choi

R&D Center
Chuncheon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine.

Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine.

Journal: BMC medicine
Published: September 29, 2022

An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.

An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.

Journal: Vaccine
Published: January 25, 2021

Assignment of opsonic values to pneumococcal reference serum 007sp and a second pneumococcal OPA calibration serum panel (Ewha QC sera panel B) for 11 serotypes.

Assignment of opsonic values to pneumococcal reference serum 007sp and a second pneumococcal OPA calibration serum panel (Ewha QC sera panel B) for 11 serotypes.

Journal: Vaccine
Published: September 15, 2020

Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine.

Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine.

Journal: PloS one
Published: April 26, 2020

Quality Improvement of Capsular Polysaccharide in Streptococcus pneumoniae by Purification Process Optimization.

Quality Improvement of Capsular Polysaccharide in Streptococcus pneumoniae by Purification Process Optimization.

Journal: Frontiers in bioengineering and biotechnology
Published: September 16, 2019

Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity.

Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity.

Journal: Biologicals : journal of the International Association of Biological Standardization
Published: July 25, 2018

Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model.

Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model.

Journal: Clinical and experimental vaccine research
Published: July 17, 2018

Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects.

Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects.

Journal: Clinical drug investigation
Published: July 07, 2018

A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.

A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.

Journal: Vaccine
Published: November 21, 2017

A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.

A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.

Journal: Vaccine
Published: May 28, 2015

Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.

Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.

Journal: Journal of Korean medical science
Published: September 25, 2013
Showing 1-11 of 11

Last Updated: 09/26/2026